DUGi: Llistar Títols | (dc.creator:"Oliveras Ferrarós, Cristina" OR dc.contributor:"Oliveras Ferrarós, Cristina" OR dc.contributor.other:"Oliveras Ferrarós, Cristina")

Llistar Títols

S'han trobat 19 ítems

Llistant ítems des de 0 a 19:

Format	Data	Títol	Autor
Format	Data	Títol	Autor
		Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
		Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
	5 juny 2018	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
	2011	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz Duran, Maria Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
	abril 2012	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts	Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
		Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts	Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
		Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts	Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
	5 juny 2018	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts	Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
	21 juny 2013	Nous mecanismes de resistència primària al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de càncer de mama (Basal/ErbB2+)	Oliveras Ferrarós, Cristina
	21 juny 2013	Nous mecanismes de resistència primària al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de càncer de mama (Basal/ErbB2+)	Oliveras Ferrarós, Cristina
		Nous mecanismes de resistència primària al trastuzumab (Herceptin): bases moleculars per a la determinació d’un nou subtipus de càncer de mama (Basal/ErbB2+)	Oliveras Ferrarós, Cristina
	2008	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Colomer, Ramon ; Llorens Duran, Rafael de ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
		Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Colomer, Ramon ; Llorens Duran, Rafael de ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
		Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Colomer, Ramon ; Llorens Duran, Rafael de ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
	5 juny 2018	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling	Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Colomer, Ramon ; Llorens Duran, Rafael de ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
	2012	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment	Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
		Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment	Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
		Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment	Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
	5 juny 2018	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment	Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel

DUGi

Portal de cerca conjunta als documents digitals de la UdG

Llistar Títols

Matèries

Autors